A Phase 2 Study of patients treated for relapsed Follicular Lymphoma: with Revlimid (Registered Trademark) consolidation added to Rituximab maintenance therapy in those remaining Positron Emission Tomography (PET) positive
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms RePLY
Most Recent Events
- 03 May 2019 Anticipated date last of participant enrollement is 30 Dec 2019.
- 26 May 2017 Status changed from not yet recruiting to recruiting.
- 01 Jul 2016 New trial record